Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis

Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by...

Descripción completa

Detalles Bibliográficos
Autores principales: Terui, Hitoshi, Moroi, Rintaro, Masamune, Atsushi, Aiba, Setsuya, Yamasaki, Kenshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885181/
https://www.ncbi.nlm.nih.gov/pubmed/36726801
http://dx.doi.org/10.1159/000529080
_version_ 1784879877623644160
author Terui, Hitoshi
Moroi, Rintaro
Masamune, Atsushi
Aiba, Setsuya
Yamasaki, Kenshi
author_facet Terui, Hitoshi
Moroi, Rintaro
Masamune, Atsushi
Aiba, Setsuya
Yamasaki, Kenshi
author_sort Terui, Hitoshi
collection PubMed
description Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy.
format Online
Article
Text
id pubmed-9885181
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-98851812023-01-31 Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis Terui, Hitoshi Moroi, Rintaro Masamune, Atsushi Aiba, Setsuya Yamasaki, Kenshi Case Rep Dermatol Single Case Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy. S. Karger AG 2023-01-27 /pmc/articles/PMC9885181/ /pubmed/36726801 http://dx.doi.org/10.1159/000529080 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Terui, Hitoshi
Moroi, Rintaro
Masamune, Atsushi
Aiba, Setsuya
Yamasaki, Kenshi
Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
title Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
title_full Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
title_fullStr Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
title_full_unstemmed Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
title_short Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
title_sort possible efficacy of vedolizumab, an anti-α4β7 integrin antibody, in palmoplantar pustulosis
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885181/
https://www.ncbi.nlm.nih.gov/pubmed/36726801
http://dx.doi.org/10.1159/000529080
work_keys_str_mv AT teruihitoshi possibleefficacyofvedolizumabanantia4b7integrinantibodyinpalmoplantarpustulosis
AT moroirintaro possibleefficacyofvedolizumabanantia4b7integrinantibodyinpalmoplantarpustulosis
AT masamuneatsushi possibleefficacyofvedolizumabanantia4b7integrinantibodyinpalmoplantarpustulosis
AT aibasetsuya possibleefficacyofvedolizumabanantia4b7integrinantibodyinpalmoplantarpustulosis
AT yamasakikenshi possibleefficacyofvedolizumabanantia4b7integrinantibodyinpalmoplantarpustulosis

Ejemplares similares